{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:49:05Z","timestamp":1772628545144,"version":"3.50.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1097\/mjt.0000000000000018","type":"journal-article","created":{"date-parts":[[2013,12,18]],"date-time":"2013-12-18T15:17:17Z","timestamp":1387379837000},"page":"e766-e772","source":"Crossref","is-referenced-by-count":9,"title":["Clinical Diagnosis, Viral PCR, and Antibiotic Utilization in Community-Acquired Pneumonia"],"prefix":"10.1097","volume":"23","author":[{"given":"Zeeshan","family":"Afzal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles G.","family":"Minard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles E.","family":"Stager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor L.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Musher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-16-20210202","first-page":"380","article-title":"Incidence and cost of CAP in a large working-age population","volume":"18","author":"Bonafede","year":"2012","journal-title":"Am J Manag Care"},{"key":"R2-16-20210202","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R3-16-20210202","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1164\/ajrccm\/148.5.1418","article-title":"Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association","volume":"148","author":"Niederman","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"R4-16-20210202","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/313954","article-title":"Practice guidelines for the management of community acquired pneumonia in adults","volume":"31","author":"Bartlett","year":"2000","journal-title":"Clin Infect Dis"},{"key":"R5-16-20210202","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.ajem.2012.12.002","article-title":"Emergency management of community-acquired bacterial pneumonia: what is new since the 2007 Infectious Diseases Society of America\/American Thoracic Society guidelines","volume":"31","author":"Moran","year":"2013","journal-title":"Am J Emerg Med"},{"key":"R6-16-20210202","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/archinternmed.2010.474","article-title":"A clinical solution to antimicrobial resistance in community-acquired pneumonia: narrowing the spectrum of antimicrobial therapy: comment on \u201cCurrent and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy\u201d","volume":"171","author":"Yu","year":"2011","journal-title":"Arch Intern Med"},{"key":"R7-16-20210202","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1164\/rccm.201002-0272CI","article-title":"Management of community-acquired pneumonia in adults","volume":"183","author":"Waterer","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"R8-16-20210202","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijantimicag.2007.06.037","article-title":"Usefulness of aetiological tests for guiding antibiotic therapy in community-acquired pneumonia","volume":"31","author":"Stralin","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"R9-16-20210202","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/cid\/cis242","article-title":"Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia","volume":"54","author":"Avdic","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R10-16-20210202","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMcp020499","article-title":"Clinical practice. Management of community-acquired pneumonia","volume":"347","author":"Halm","year":"2002","journal-title":"N Engl J Med"},{"key":"R12-16-20210202","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1016\/S0924-8579(05)80324-3","article-title":"Principles of appropriate antibiotic use","volume":"26","author":"Niederman","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"R13-16-20210202","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1525-1497.2005.0148.x","article-title":"Trends in antibiotic prescribing for adults in the United States\u20131995 to 2002","volume":"20","author":"Roumie","year":"2005","journal-title":"J Gen Intern Med"},{"key":"R14-16-20210202","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jinf.2013.03.003","article-title":"Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study","volume":"67","author":"Musher","year":"2013","journal-title":"J Infect"},{"key":"R15-16-20210202","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s100960050418","article-title":"New directions for future studies of community-acquired pneumonia: optimizing impact on patient care","volume":"18","author":"Vergis","year":"1999","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R16-16-20210202","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/thorax.56.4.296","article-title":"Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines","volume":"56","author":"Lim","year":"2001","journal-title":"Thorax"},{"key":"R17-16-20210202","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1093\/cid\/cir045","article-title":"Diagnostic tests for agents of community-acquired pneumonia","volume":"52","author":"Bartlett","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R18-16-20210202","first-page":"300","article-title":"Limitations of diagnostic testing in the initial management of patients with community-acquired pneumonia","volume":"12","author":"San Pedro","year":"1997","journal-title":"Semin Respir Infect"},{"key":"R19-16-20210202","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/thx.2004.030411","article-title":"Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study","volume":"60","author":"Van der Eerden","year":"2005","journal-title":"Thorax"},{"key":"R20-16-20210202","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1164\/ajrccm.160.1.9806048","article-title":"Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia","volume":"160","author":"Sanyal","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"R21-16-20210202","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1086\/648678","article-title":"Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods","volume":"50","author":"Johansson","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R22-16-20210202","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1086\/497134","article-title":"Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection","volume":"41","author":"Oosterheert","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R23-16-20210202","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.idc.2012.11.008","article-title":"What is the role of antimicrobial stewardship in improving outcomes of patients with CAP?","volume":"27","author":"Nussenblatt","year":"2013","journal-title":"Infect Dis Clin North Am"},{"key":"R24-16-20210202","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1378\/chest.07-0164","article-title":"Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule","volume":"131","author":"Kanwar","year":"2007","journal-title":"Chest"},{"key":"R25-16-20210202","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jac\/dkp131","article-title":"Outcomes of early switching from intravenous to oral antibiotics on medical wards","volume":"64","author":"Mertz","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R26-16-20210202","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S0954-6111(98)90351-1","article-title":"Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis","volume":"92","author":"Omidvari","year":"1998","journal-title":"Respir Med"},{"key":"R27-16-20210202","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1086\/512174","article-title":"An outbreak of severe Clostridium-difficile-associated diseases possibility related to inappropriate antimicrobial therapy for community-acquired pneumonia","volume":"28","author":"Polgreen","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R28-16-20210202","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R29-16-20210202","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1056\/NEJMcp011603","article-title":"Clinical practice. Antibiotic-associated diarrhea","volume":"346","author":"Bartlett","year":"2002","journal-title":"N Engl J Med"},{"key":"R30-16-20210202","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1001\/archinte.164.5.502","article-title":"Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia","volume":"164","author":"Ros\u00f3n","year":"2004","journal-title":"Arch Intern Med"},{"key":"R31-16-20210202","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM199708143370701","article-title":"The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance","volume":"337","author":"Sepp\u00e4l\u00e4","year":"1997","journal-title":"N Engl J Med"},{"key":"R32-16-20210202","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJM199907223410403","article-title":"Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network","volume":"34","author":"Chen","year":"1999","journal-title":"N Engl J Med"},{"key":"R33-16-20210202","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11908-013-0327-3","article-title":"Determining the duration of therapy for patients with community-acquired pneumonia","volume":"15","author":"Scalera","year":"2013","journal-title":"Curr Infect Dis Rep"},{"key":"R34-16-20210202","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/bmj.332.7554.1355","article-title":"Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomized double blind study","volume":"332","author":"El Moussaoui","year":"2006","journal-title":"BMJ"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0000000000000018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:24:05Z","timestamp":1620962645000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201605000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0000000000000018","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}